PSTPIP1 (O43586) variants and mutations
PSTPIP1 (also known as O43586) is a human protein-coding gene encoding a proline-serine-threonine phosphatase-interacting protein 1 protein. It organizes cytoskeletal and inflammasome-associated protein interactions in myeloid cells and can influence pyrin-dependent inflammatory signaling. Gain-of-function variants cause PAPA syndrome and related PSTPIP1-associated autoinflammatory diseases with sterile arthritis and inflammatory skin lesions. This analysis covers 790 PSTPIP1 variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes pyogenic arthritis-pyoderma gangrenosum-acne syndrome, Pyogenic arthritis - pyoderma gangrenosum - acne, and hyperzincemia with functional zinc depletion. Example PSTPIP1 variants include M2I, M2T, and M2L.
Variant analysis overview
- Gene: PSTPIP1
- Protein: O43586
- UniProt accession: O43586
- Organism: Homo sapiens
- Variants analyzed: 790
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 617 unspecified-consequence records; 7 frameshift variants; 112 missense variants; 38 synonymous variants; 1 splice-region variants; 9 stop-gained variants; 1 splice acceptor variant; 5 substitution
- Prediction scores: 679 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: pyogenic arthritis-pyoderma gangrenosum-acne syndrome, Pyogenic arthritis - pyoderma gangrenosum - acne, hyperzincemia with functional zinc depletion, Behcet disease, type 2 diabetes mellitus, Recurrent infections - inflammatory syndrome due to zinc metabolism disorder, rheumatoid arthritis, coronary artery disorder, Abnormality of the skeletal system, migraine disorder, cholelithiasis, exfoliation syndrome.
Protein structure and variant hotspots
- Protein features: 2 domains; 2 post-translational modification sites.
- Structural context: 616 variants have structural context.
- PTM context: 1 variants overlap post-translational modification sites.
- Experimental data: 56 protein positions have experimental scores. Source: PSTPIP1 SH3 domain domainome 1.0.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PSTPIP1 variants
Examples include M2I, M2T, M2L, P3H, P3S, P3L, P3P, P3A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M2I (p.Met2Ile), rs770056297, ClinGen CA7675642, ClinVar RCV003362596, ExAC rs770056297, AlphaMissense 0.57, MetaLR 0.13, Uncertain significance, Inborn genetic diseases
- M2T (p.Met2Thr), rs541085532, ClinGen CA7675641, ClinVar RCV000897721, ClinVar RCV002264067, MetaLR 0.12, MetaSVM -0.98, Conflicting interpretations, Autoinflammatory syndrome; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- M2L (p.Met2Leu), gnomAD 15-76995577-A-C, MetaLR 0.12, MetaSVM -0.98
- P3H (p.Pro3His), TOPMed rs1453844121, gnomAD rs1453844121, MetaLR 0.09, MetaSVM -1.01
- P3S (p.Pro3Ser), rs1057519224, ClinGen CA16043873, ClinVar RCV000416193, ClinVar RCV005055954, MetaLR 0.06, MetaSVM -1.01, Uncertain significance, not provided; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- P3L (p.Pro3Leu), rs997027588, gnomAD 15-76994812-C-T, CADD 2.42, SIFT 0.01
- P3P (p.Pro3Pro), gnomAD 15-76994813-T-A, CADD 5.62
- P3A (p.Pro3Ala), rs1369094571, gnomAD 15-76995462-A-AG, CADD 16.90
- P3T (p.Pro3Thr), gnomAD 15-76995469-CCTGG, CADD 16.80
- P3Q (p.Pro3Gln), gnomAD 15-76995476-C-A, CADD 16.10, SIFT 0.03
- Q4P (p.Gln4Pro), Ensembl rs1596029075
- L5M (p.Leu5Met), gnomAD 15-76995415-C-A, CADD 15.50, SIFT 0.09
- L5L (p.Leu5Leu), gnomAD 15-76995415-C-T, CADD 16.00
- L5V (p.Leu5Val), rs1345924057, gnomAD 15-76995415-C-G, CADD 15.60, SIFT 0.09
- Q6K (p.Gln6Lys), gnomAD rs1258036988, MetaLR 0.08, MetaSVM -1.05
- Q6L (p.Gln6Leu), rs2075560082, ClinGen CA393516140, ClinVar RCV003006185, TOPMed rs2075560082, AlphaMissense 0.10, MetaLR 0.06, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- Q6R (p.Gln6Arg), rs2075560082, ClinGen CA393516141, ClinVar RCV003048743, AlphaMissense 0.10, MetaLR 0.06, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- K8E (p.Lys8Glu), rs199800583, ClinGen CA7675645, ClinVar RCV000805546, 1000Genomes rs199800583, MetaLR 0.12, MetaSVM -1.02, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- D9N (p.Asp9Asn), rs2075560223, ClinGen CA393516168, ClinVar RCV002264494, Ensembl rs2075560223, MetaLR 0.09, MetaSVM -1.06, Uncertain significance, Autoinflammatory syndrome
- D9Y (p.Asp9Tyr), Ensembl rs2075560223, Uncertain significance
- D9A (p.Asp9Ala), rs1353310784, gnomAD 15-76994796-GACAG, CADD 4.95
- D9G (p.Asp9Gly), gnomAD 15-76994797-A-G, CADD 2.09, SIFT 0.00
- A10D (p.Ala10Asp), ExAC rs775041579, TOPMed rs775041579, gnomAD rs775041579, MetaLR 0.17, MetaSVM -0.93, Uncertain significance
- A10V (p.Ala10Val), rs775041579, ClinGen CA7675646, ClinVar RCV001037172, ClinVar RCV004031022, MetaLR 0.10, MetaSVM -1.00, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome; Inborn genetic diseases
- A10T (p.Ala10Thr), gnomAD 15-76995601-G-A, MetaLR 0.10, MetaSVM -0.96
- A10A (p.Ala10Ala), gnomAD 15-76995603-C-T, CADD 13.50
- F11S (p.Phe11Ser), rs762264110, ClinGen CA393516196, ClinVar RCV003613152, ExAC rs762264110, AlphaMissense 0.81, MetaLR 0.29, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- F11Y (p.Phe11Tyr), ExAC rs762264110, gnomAD rs762264110, Uncertain significance
- W12S (p.Trp12Ser), rs2542598691, ClinGen CA393516209, ClinVar RCV003612853, MetaLR 0.31, MetaSVM -0.36, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- W12R (p.Trp12Arg), rs1388644352, gnomAD 15-76995505-T-C, CADD 17.90, SIFT 0.00
- W12C (p.Trp12Cys), rs1386483084, gnomAD 15-76995507-G-T, CADD 15.80, SIFT 0.00
- W12L (p.Trp12Leu), rs920122436, gnomAD 15-76995536-G-T, CADD 10.50, SIFT 0.02
- W12* (p.Trp12Ter), gnomAD 15-76995608-G-A, CADD 41.00
- C13F (p.Cys13Phe), rs2152678700, ClinGen CA2573054108, ClinVar RCV001803666, Ensembl rs2152678700, MetaLR 0.11, MetaSVM -0.94, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- C13G (p.Cys13Gly), rs376128040, ClinGen CA7675687, ClinVar RCV000231124, ClinVar RCV001514746, MetaLR 0.03, MetaSVM -1.07, Conflicting interpretations, not provided; Inborn genetic diseases; Autoinflammatory syndrome
- C13W (p.Cys13Trp), rs2076087868, ClinGen CA393518129, ClinVar RCV001316545, Ensembl rs2076087868, AlphaMissense 0.69, MetaLR 0.13, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- C13R (p.Cys13Arg), rs899879477, gnomAD 15-76994802-T-C, CADD 8.41, SIFT 0.00
- C13C (p.Cys13Cys), rs148361080, gnomAD 15-76994804-C-T, CADD 2.02
- C13Q (p.Cys13Gln), gnomAD 15-76995426-CTGCC, CADD 17.90
- C13Y (p.Cys13Tyr), gnomAD 15-76995428-G-A, CADD 18.60, SIFT 0.00
- C13* (p.Cys13Ter), gnomAD 15-76995429-C-A, CADD 15.20
- C13P (p.Cys13Pro), gnomAD 15-77018141-GTCAC, CADD 24.90
- R14K (p.Arg14Lys), rs2076087921, ClinGen CA393518133, ClinVar RCV002299624, TOPMed rs2076087921, MetaLR 0.01, MetaSVM -0.94, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- R14R (p.Arg14Arg), gnomAD 15-76994801-A-G, CADD 4.78
- R14T (p.Arg14Thr), gnomAD 15-76994809-G-C, CADD 4.25, SIFT 0.08
- R14S (p.Arg14Ser), rs867293179, gnomAD 15-76995421-C-A, CADD 9.98, SIFT 0.08
- R14C (p.Arg14Cys), rs867293179, gnomAD 15-76995421-C-T, CADD 9.78, SIFT 0.03
- R14L (p.Arg14Leu), rs764052990, gnomAD 15-76995421-CG-C, CADD 8.25
- R14G (p.Arg14Gly), rs867293179, gnomAD 15-76995421-C-G, CADD 9.00, SIFT 0.10
- R14H (p.Arg14His), rs1200264724, gnomAD 15-76995422-G-A, CADD 10.70, SIFT 0.06
- R14W (p.Arg14Trp), gnomAD 15-77018151-A-T, MetaLR 0.05, MetaSVM -1.09
- R14M (p.Arg14Met), gnomAD 15-77018152-G-T, MetaLR 0.03, MetaSVM -1.07
- D15E (p.Asp15Glu), gnomAD rs1295436726, MetaLR 0.04, MetaSVM -1.09
- D15N (p.Asp15Asn), rs934905433, Ensembl rs934905433, AlphaMissense 0.33, MetaLR 0.13, Variant assessed as somatic; moderate impact.
- D15Y (p.Asp15Tyr), gnomAD 15-77018154-G-T, MetaLR 0.15, MetaSVM -0.76
- D15D (p.Asp15Asp), gnomAD 15-77018156-C-T, CADD 11.80
- F16C (p.Phe16Cys), Ensembl rs2076088091
- F16L (p.Phe16Leu), rs2152678710, ClinGen CA393518147, ClinVar RCV002264496, Ensembl rs2152678710, MetaLR 0.11, MetaSVM -1.04, Uncertain significance, Autoinflammatory syndrome
- F16F (p.Phe16Phe), rs776988502, gnomAD 15-77018159-C-T, CADD 13.00
- T17I (p.Thr17Ile), rs1235260030, ClinGen CA393518158, ClinVar RCV000824000, gnomAD rs1235260030, MetaLR 0.09, MetaSVM -1.06, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- T17S (p.Thr17Ser), gnomAD 15-77018160-A-T, MetaLR 0.19, MetaSVM -0.76
- T17A (p.Thr17Ala), gnomAD 15-77018160-A-G, MetaLR 0.13, MetaSVM -0.99
- T17K (p.Thr17Lys), gnomAD 15-77018161-C-A, MetaLR 0.21, MetaSVM -0.78
- T17T (p.Thr17Thr), gnomAD 15-77018162-A-G, CADD 4.38
- A18D (p.Ala18Asp), rs1277032061, ClinGen CA393518164, ClinVar RCV002292129, MetaLR 0.04, MetaSVM -1.02, Uncertain significance, not provided
- A18V (p.Ala18Val), gnomAD rs1277032061
- A18E (p.Ala18Glu), gnomAD 15-76995443-C-A, CADD 16.90, SIFT 0.00
- A18T (p.Ala18Thr), rs771172891, gnomAD 15-76995451-G-A, CADD 12.60, SIFT 0.00
- A18G (p.Ala18Gly), gnomAD 15-76995452-C-G, CADD 9.70, SIFT 0.00
- A18A (p.Ala18Ala), gnomAD 15-76995453-C-G, CADD 13.80
- A18S (p.Ala18Ser), gnomAD 15-77018163-G-T, MetaLR 0.03, MetaSVM -1.03
- H19R (p.His19Arg), rs759653276, gnomAD 15-76995521-A-G, CADD 7.59, SIFT 0.15
- H19N (p.His19Asn), gnomAD 15-77018166-C-A, MetaLR 0.02, MetaSVM -0.95
- H19Y (p.His19Tyr), gnomAD 15-77018166-C-T, MetaLR 0.07, MetaSVM -1.12
- H19Q (p.His19Gln), gnomAD 15-77018168-C-A, MetaLR 0.04, MetaSVM -1.06
- H19H (p.His19His), gnomAD 15-77018168-C-T, CADD 8.94
- T20A (p.Thr20Ala), gnomAD rs2076088348, AlphaMissense 0.06, MetaLR 0.01
- T20K (p.Thr20Lys), cosmic curated COSV51201, 1000Genomes rs553718554, ExAC rs553718554, TOPMed rs553718554, MetaLR 0.04, MetaSVM -1.06, Uncertain significance
- T20M (p.Thr20Met), rs553718554, ClinGen CA7675689, ClinVar RCV000299645, ClinVar RCV002262996, MetaLR 0.06, MetaSVM -1.03, Conflicting interpretations, Autoinflammatory syndrome; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- T20P (p.Thr20Pro), rs2076088348, ClinGen CA393518173, ClinVar RCV003613102, AlphaMissense 0.06, MetaLR 0.01, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- T20T (p.Thr20Thr), rs572721166, gnomAD 15-77018171-G-T, CADD 2.00
- G21D (p.Gly21Asp), TOPMed rs2076088571, MetaLR 0.40, MetaSVM -0.05
- G21E (p.Gly21Glu), rs2152678736, ClinGen CA2573151179, ClinVar RCV002021579, Ensembl rs2152678736, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- G21R (p.Gly21Arg), gnomAD 15-76994814-G-C, CADD 2.81, SIFT 0.00
- G21A (p.Gly21Ala), gnomAD 15-76994815-G-C, CADD 2.79, SIFT 0.00
- G21C (p.Gly21Cys), rs2075554964, gnomAD 15-76995424-G-T, CADD 6.97, SIFT 0.00
- G21V (p.Gly21Val), rs1262819741, gnomAD 15-76995425-G-T, CADD 18.50, SIFT 0.00
- G21G (p.Gly21Gly), gnomAD 15-76995426-C-A, CADD 16.60
- G21S (p.Gly21Ser), rs2458253, gnomAD 15-76995448-G-A, CADD 14.10, SIFT 0.24
- Y22H (p.Tyr22His), gnomAD 15-77018175-T-C, MetaLR 0.11, MetaSVM -0.97
- Y22C (p.Tyr22Cys), gnomAD 15-77018176-A-G, MetaLR 0.12, MetaSVM -0.97
- Y22Y (p.Tyr22Tyr), rs373516507, gnomAD 15-77018177-C-T, CADD 1.46
- Y22* (p.Tyr22Ter), gnomAD 15-77018177-C-A, CADD 25.80
- E23K (p.Glu23Lys), cosmic curated COSV10957, gnomAD rs1246839429, MetaLR 0.26, MetaSVM -0.66, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- E23V (p.Glu23Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E23* (p.Glu23Ter), gnomAD 15-76995460-G-T, CADD 10.50
- E23G (p.Glu23Gly), gnomAD 15-76995461-A-G, CADD 5.86, SIFT 0.21
- E23E (p.Glu23Glu), gnomAD 15-76995462-A-G, CADD 17.20
- E23Q (p.Glu23Gln), gnomAD 15-77018178-G-C, MetaLR 0.29, MetaSVM -0.48
- E23D (p.Glu23Asp), gnomAD 15-77018180-G-T, MetaLR 0.07, MetaSVM -1.07
- V24V (p.Val24Val), rs1454332232, gnomAD 15-76995441-T-A, CADD 17.00
- V24M (p.Val24Met), gnomAD 15-77018181-G-A, MetaLR 0.06, MetaSVM -1.00
- V24L (p.Val24Leu), gnomAD 15-77018181-G-T, MetaLR 0.04, MetaSVM -1.03
- L25P (p.Leu25Pro), rs2076088849, ClinGen CA393518208, ClinVar RCV003611265, TOPMed rs2076088849, MetaLR 0.19, MetaSVM -0.69, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- L25F (p.Leu25Phe), rs1306187132, gnomAD 15-76995430-C-T, CADD 18.20, SIFT 0.00
- L25H (p.Leu25His), gnomAD 15-76995431-T-A, CADD 18.20, SIFT 0.00
- L25L (p.Leu25Leu), rs1191640172, gnomAD 15-76995433-C-T, CADD 19.00
- L25M (p.Leu25Met), gnomAD 15-77018184-C-A, MetaLR 0.12, MetaSVM -0.99
- L26L (p.Leu26Leu), gnomAD 15-77018187-C-T, CADD 10.30
- L26M (p.Leu26Met), gnomAD 15-77018187-C-A, MetaLR 0.11, MetaSVM -0.91
- L26P (p.Leu26Pro), gnomAD 15-77018188-T-C, MetaLR 0.11, MetaSVM -0.99
- Q27* (p.Gln27Ter), TOPMed rs2076088910, CADD 37.00
- Q27L (p.Gln27Leu), TOPMed rs1463368534
- Q27K (p.Gln27Lys), gnomAD 15-77018190-C-A, MetaLR 0.12, MetaSVM -1.01
- Q27H (p.Gln27His), gnomAD 15-77018192-G-T, MetaLR 0.20, MetaSVM -0.72
- Q27Q (p.Gln27Gln), gnomAD 15-77018192-G-A, CADD 9.55
- R28Q (p.Arg28Gln), rs750445188, ClinGen CA7675694, cosmic curated COSV10726, ClinVar RCV001931287, MetaLR 0.14, MetaSVM -0.80, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- R28W (p.Arg28Trp), rs767330325, ClinGen CA7675693, ClinVar RCV000233989, ClinVar RCV001062059, MetaLR 0.13, MetaSVM -0.82, Uncertain significance, not provided; Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- R28L (p.Arg28Leu), gnomAD 15-76995458-G-T, CADD 0.53, SIFT 0.14
- R28R (p.Arg28Arg), gnomAD 15-76995459-G-A, CADD 10.80
- L29I (p.Leu29Ile), gnomAD rs2076089195, MetaLR 0.10, MetaSVM -1.01
- L29P (p.Leu29Pro), rs1375790630, ClinGen CA393518230, ClinVar RCV002008860, gnomAD rs1375790630, MetaLR 0.15, MetaSVM -0.81, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- L29L (p.Leu29Leu), gnomAD 15-77018198-T-A, CADD 10.70
- L30L (p.Leu30Leu), rs764392248, gnomAD 15-76995481-C-T, CADD 13.90
- L30P (p.Leu30Pro), rs753370729, gnomAD 15-76995482-T-C, CADD 16.70, SIFT 0.11
- L30M (p.Leu30Met), gnomAD 15-77018199-C-A, MetaLR 0.10, MetaSVM -0.81
- L30Q (p.Leu30Gln), rs1263340623, gnomAD 15-77018199-CTGGA, CADD 29.50
- D31Y (p.Asp31Tyr), gnomAD 15-77018202-G-T, MetaLR 0.12, MetaSVM -0.94
- D31N (p.Asp31Asn), gnomAD 15-77018202-G-A, MetaLR 0.08, MetaSVM -1.11
- D31G (p.Asp31Gly), gnomAD 15-77018203-A-G, MetaLR 0.09, MetaSVM -1.08
- D31D (p.Asp31Asp), gnomAD 15-77018204-T-C, CADD 1.22
- G32D (p.Gly32Asp), cosmic curated COSV51205, gnomAD rs1477578839, MetaLR 0.20, MetaSVM -0.58
- G32S (p.Gly32Ser), rs2542743003, ClinGen CA393518245, ClinVar RCV003503019, MetaLR 0.14, MetaSVM -0.93, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- G32R (p.Gly32Arg), gnomAD 15-76995463-G-A, CADD 17.70, SIFT 0.03
- G32W (p.Gly32Trp), gnomAD 15-76995463-G-T, CADD 17.40, SIFT 0.01
- G32E (p.Gly32Glu), rs557528832, gnomAD 15-76995464-G-A, CADD 16.60, SIFT 0.03
- G32V (p.Gly32Val), rs557528832, gnomAD 15-76995464-G-T, CADD 16.30, SIFT 0.19
- G32A (p.Gly32Ala), rs557528832, gnomAD 15-76995464-G-C, CADD 16.40, SIFT 0.33
- G32G (p.Gly32Gly), rs1028909916, gnomAD 15-76995465-G-A, CADD 15.80
- G32* (p.Gly32Ter), gnomAD 15-76995493-G-T, CADD 18.30
- G32C (p.Gly32Cys), gnomAD 15-77018205-G-T, MetaLR 0.20, MetaSVM -0.58
- R33T (p.Arg33Thr), gnomAD 15-77018209-G-C, MetaLR 0.06, MetaSVM -1.14
- R33M (p.Arg33Met), gnomAD 15-77018209-G-T, MetaLR 0.10, MetaSVM -1.00
- R33S (p.Arg33Ser), gnomAD 15-77018210-G-T, MetaLR 0.06, MetaSVM -1.13
- R33R (p.Arg33Arg), gnomAD 15-77018210-G-A, CADD 12.00
- K34N (p.Lys34Asn), ExAC rs760375102, gnomAD rs760375102, MetaLR 0.08, MetaSVM -1.08
- K34T (p.Lys34Thr), gnomAD 15-77018212-A-C, MetaLR 0.07, MetaSVM -1.10
- K34K (p.Lys34Lys), gnomAD 15-77018213-G-A, CADD 12.10
- M35L (p.Met35Leu), gnomAD rs1390777922, MetaLR 0.06, MetaSVM -1.10
- M35V (p.Met35Val), gnomAD rs1390777922, MetaLR 0.07, MetaSVM -1.09, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- M35I (p.Met35Ile), gnomAD 15-77018216-G-A, MetaLR 0.09, MetaSVM -1.01
- C36G (p.Cys36Gly), TOPMed rs938956023, gnomAD rs938956023, MetaLR 0.16, MetaSVM -0.78
- C36C (p.Cys36Cys), rs1328055078, gnomAD 15-76995504-C-T, CADD 17.00
- C36R (p.Cys36Arg), gnomAD 15-77018217-T-C, MetaLR 0.16, MetaSVM -0.78
- C36Y (p.Cys36Tyr), gnomAD 15-77018218-G-A, MetaLR 0.17, MetaSVM -0.71
- C36F (p.Cys36Phe), gnomAD 15-77018218-G-T, MetaLR 0.17, MetaSVM -0.71
- C36* (p.Cys36Ter), gnomAD 15-77018219-C-A, CADD 37.00
- C36W (p.Cys36Trp), gnomAD 15-77018219-C-G, MetaLR 0.15, MetaSVM -0.80
- K37K (p.Lys37Lys), rs2152678775, gnomAD 15-77018222-A-G, CADD 9.06
- D38V (p.Asp38Val), gnomAD rs2076089606, MetaLR 0.28, MetaSVM -0.48
- D38N (p.Asp38Asn), gnomAD 15-77018223-G-A, MetaLR 0.27, MetaSVM -0.51
- D38Y (p.Asp38Tyr), gnomAD 15-77018223-G-T, MetaLR 0.26, MetaSVM -0.60
- D38G (p.Asp38Gly), gnomAD 15-77018224-A-G, MetaLR 0.28, MetaSVM -0.49
- D38D (p.Asp38Asp), gnomAD 15-77018225-C-T, CADD 7.73
- D38E (p.Asp38Glu), gnomAD 15-77018225-C-A, MetaLR 0.07, MetaSVM -1.02
- M39L (p.Met39Leu), TOPMed rs2076089652, NCI-TCGA Cosmic COSV9914, cosmic curated COSV99143, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- M39T (p.Met39Thr), gnomAD rs1260831469, MetaLR 0.10, MetaSVM -0.82
- M39V (p.Met39Val), TOPMed rs2076089652, MetaLR 0.03, MetaSVM -1.02, Uncertain significance, Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
- M39I (p.Met39Ile), gnomAD 15-77018228-G-A, MetaLR 0.05, MetaSVM -1.03
- E40K (p.Glu40Lys), gnomAD rs1455541356, MetaLR 0.09, MetaSVM -1.10
- E40* (p.Glu40Ter), gnomAD 15-77018229-G-T, CADD 45.00
- E40G (p.Glu40Gly), gnomAD 15-77018230-A-G, MetaLR 0.12, MetaSVM -0.93
- E40D (p.Glu40Asp), gnomAD 15-77018231-G-T, MetaLR 0.11, MetaSVM -1.00
- E40E (p.Glu40Glu), gnomAD 15-77018231-G-A, CADD 9.26
- E41K (p.Glu41Lys), cosmic curated COSV51206, gnomAD rs1318668141, MetaLR 0.09, MetaSVM -1.10
- E41* (p.Glu41Ter), gnomAD 15-77018232-G-T, CADD 44.00
- E41G (p.Glu41Gly), gnomAD 15-77018233-A-G, MetaLR 0.10, MetaSVM -1.07
- E41E (p.Glu41Glu), rs766141606, gnomAD 15-77018234-G-A, CADD 8.96
- E41D (p.Glu41Asp), gnomAD 15-77018234-G-T, MetaLR 0.02, MetaSVM -1.01
- L42P (p.Leu42Pro), rs1365380083, gnomAD 15-76995491-T-C, CADD 12.50, SIFT 0.04
Public PSTPIP1 analysis runs
- PSTPIP1 analysis run — PSTPIP1 (790 variants) — completed 2026-08-20